Cardio Diagnostics Holdings Inc CDIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call
Cardio Diagnostics’ Whitepaper Examines Clinical Blind Spot in Coronary Heart Disease Detection and Care
Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
Trading Information
- Previous Close Price
- $1.71
- Day Range
- $1.67–1.76
- 52-Week Range
- $0.97–7.91
- Bid/Ask
- $1.41 / $2.10
- Shares Outstanding
- 2.96M
- Market Cap
- $5.00M
- Volume/Avg
- 1 / 28,222
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 294.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.cdio.ai
Valuation
Metric | CDIO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.87 |
Price/Sales | 294.48 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CDIO |
|---|---|
Quick Ratio | 15.81 |
Current Ratio | 17.44 |
Interest Coverage | −564.93 |
Quick Ratio
CDIO
Profitability
Metric | CDIO |
|---|---|
Return on Assets (Normalized) | −79.62% |
Return on Equity (Normalized) | −85.95% |
Return on Invested Capital (Normalized) | −81.80% |
Return on Assets
CDIO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|!gBLVr | LOCK|@Mr$ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%>NM$M | LOCK|&<G! | $98B | |||
| Moderna Inc MRNA | LOCK|Kcz@HsB | LOCK|T^ | $80B | |||
| argenx SE ADR ARGX | LOCK|p&FN?S | LOCK|?@j | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|V^SRK& | LOCK|^lX | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#SfKrK& | LOCK|z!s#@ | $31B | |||
| Incyte Corp INCY | LOCK|pn?R#Fk | LOCK|%!@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|QnPXQ& | LOCK|!R | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@Hp!VfK | LOCK|dyTlG | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|jrKsY? | LOCK|Kj! | $16B |